Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
BERKELEY, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 14, 2016, at 10:30 am Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 Mike Beyer Sam Brown, Inc. 312 961 2502 [email protected]
